Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:05 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Study Clear all
Enrolling by invitation Phase 3 Interventional

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

NCT07444489
View directory record Official record
Conditions
Antibody-mediated Rejection, Microvascular Inflammation
Interventions
Felzartamab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo
Drug · Device · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Terminated Phase 1 Interventional

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

NCT01816659
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Metformin ER
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 4 Interventional Results available

Open-Labeled PK-PD Studies of Metoprolol ER

NCT02417246
View directory record Official record
Conditions
Blood Pressure
Interventions
brand name metoprolol ER, Generic A, Generic B
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Nov 3, 2026, 2:05 PM EST
Active, not recruiting Phase 2 Interventional

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Tebapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Lakewood, California • Los Angeles, California • Redlands, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Terminated Phase 3 Interventional Results available

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT01103362
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
88
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Nov 3, 2026, 2:05 PM EST
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ALXN1720, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Terminated Phase 3 Interventional Results available

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

NCT03532542
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Casimersen, Golodirsen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 23 Years · Male only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Takeda
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

NCT04966741
View directory record Official record
Conditions
Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Nov 3, 2026, 2:05 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Extension for 43USSA1812

NCT04595331
View directory record Official record
Conditions
Cheek, Wrinkle
Interventions
Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
21 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Encino, California • Redondo Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

NCT04278924
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Placebo, TAK-079
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Nov 3, 2026, 2:05 PM EST
Recruiting Phase 3 Interventional

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

NCT05754450
View directory record Official record
Conditions
Leukocyte Adhesion Deficiency
Interventions
AVTX-803
Drug
Lead sponsor
AUG Therapeutics
Industry
Eligibility
6 Months to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Nov 3, 2026, 2:05 PM EST
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Trofinetide for Rett Syndrome

NCT04776746
View directory record Official record
Conditions
Rett Syndrome
Interventions
trofinetide
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 21 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Nov 3, 2026, 2:05 PM EST
Terminated Phase 2 Interventional Results available

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

NCT05476783
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TB006
Drug
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
San Diego, California • Delray Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence

NCT01690546
View directory record Official record
Conditions
Opiate Dependence
Interventions
very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
Drug
Lead sponsor
Paolo Mannelli
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

NCT00410124
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
RAD001, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
31
States / cities
Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

NCT01114217
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 3 Interventional

A Study of Pain Relief in Low Back Pain

NCT00325949
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Extended release hydrocodone and acetaminophen (Vicodin CR), hydrocodone/acetaminophen extended release (Vicodin CR), placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 75 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Hueytown, Alabama • Phoenix, Arizona • Tempe, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Nov 3, 2026, 2:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Treatment for Moderate to Severe Acne

NCT01206348
View directory record Official record
Conditions
Acne
Interventions
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years to 30 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Santa Monica, California • Hockessin, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Nov 3, 2026, 2:05 PM EST